# A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies

> **NCT01416623** · PHASE1 · TERMINATED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 44 (actual)

## Conditions studied

- Advanced Solid Cancer

## Interventions

- **DRUG:** henatinib

## Key facts

- **NCT ID:** NCT01416623
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2012-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01416623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01416623, "A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01416623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*